Removal from labeling of 60-mg citalopram dose

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 7, 2012, Pages 784-786

  Temple, Robert ^a   Laughren, Thomas ^a   Stockbridge, Norman ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; BEPRIDIL; CISAPRIDE; CITALOPRAM; DOFETILIDE; ESCITALOPRAM; QUINIDINE; SOTALOL; TERFENADINE;

DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG LABELING; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HUMAN; LETTER; MAJOR DEPRESSION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; TORSADE DES POINTES; TREATMENT RESPONSE;

EID: 84863555299     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3289     Document Type: Letter

References (8)

1. McKean AJ, Sola CL, Galardy C, Kung S, Lineberry TW. Reconciling the risk of QT interval prolongation in antidepressants. Pharmacoepidemiol Drug Saf 2012; 21: 329-330.
2. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011; 20: 903-913.
3. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.
4. de Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol 2009; 132: 226-228.
5. Kanjanauthai S, Kanluen T, Chareonthaitawee P. Citalopram induced torsae de pointes, a rare life threatening side effect. Int J Cardiol 2008; 131: e33-e34.
6. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2012; 21: 331-332.
7. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. NEJM 2009; 360: 225-235.
8. Kasper S, Moller H, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010; 260: 59-68.